News | July 27, 2025
Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
She was Group Chief Marketing Officer at CKA Birla Group in her last role
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
Combined strength of two brands across 11 states to elevate patient care delivery and access to doctors
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
The new Zigly center features and offers comprehensive veterinary services
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Subscribe To Our Newsletter & Stay Updated
